You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory AML

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,

Not yet recruiting
  • Acute Myeloid Leukemia
  • +10 more
  • (no location specified)
Feb 17, 2023

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +3 more
Aug 4, 2022

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting
  • CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 14, 2022

MDS, Acute Myeloid Leukemia Trial in New Haven (AG-120, Nivolumab)

Withdrawn
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • New Haven, Connecticut
    Yale Cancer Center
Jan 6, 2022

Acute Myeloid Leukemia, in Relapse Trial in Baltimore, Chapel Hill (pembrolizumab,)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia, in Relapse
  • Baltimore, Maryland
  • +1 more
Aug 10, 2022

Acute Myeloid Leukemia Trial (ABBV-787)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 29, 2023

Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)

Recruiting
  • Core Binding Factor Acute Myeloid Leukemia
  • KIT Mutation-Related Tumors
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Apr 7, 2023

Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib

Recruiting
  • Follicular Lymphoma (FL)
  • +6 more
  • voruciclib monotherapy
  • voruciclib and venetoclax
  • Duarte, California
  • +10 more
Aug 10, 2022

Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

Recruiting
  • Acute Myeloid Leukemia (Relapsed/Refractory)
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 16, 2023

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,

Recruiting
  • Stem Cell Transplant Complications
  • +4 more
  • Radiation
  • +7 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • venetoclax combining chidamide and azacitidine (VCA)
  • Xiamen, Fujian, China
    Bing Xu
Aug 1, 2022

AML, Childhood Trial in United States (Nivolumab, 5-azacytidine)

Active, not recruiting
  • AML, Childhood
  • Los Angeles, California
  • +11 more
Oct 10, 2022

Relapsed/Refractory AML Trial in United States (CLN-049)

Recruiting
  • Relapsed/Refractory AML
  • Tampa, Florida
  • +3 more
Dec 2, 2021

Relapsed/Refractory AML, AML, Adult, MDS Trial in United States (NKX101 - CAR NK cell therapy)

Recruiting
  • Relapsed/Refractory AML
  • +3 more
  • NKX101 - CAR NK cell therapy
  • Denver, Colorado
  • +6 more
Apr 8, 2022

Advanced Solid Tumor, Relapsed AML, Refractory AML Trial in Hong Kong (NEI-01)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Hong Kong, Hong Kong
    The University of Hong Kong Phase I Clinical Trials Centre
May 6, 2022

Acute Myeloid Leukemia Trial in Xuzhou (allogenic NK cells)

Recruiting
  • Acute Myeloid Leukemia
  • allogenic NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Leukemia, Myeloid, Acute Trial in United States (VCAR33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • VCAR33
  • La Jolla, California
  • +9 more
Aug 14, 2023

AML, MDS Trial in Tianjin (XZB-0004)

Not yet recruiting
  • AML
  • MDS
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

Recruiting
  • Leukemia
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +9 more
Sep 9, 2022

AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in United States (APG-115, 5-azacitidine)

Recruiting
  • AML
  • +6 more
  • Gilbert, Arizona
  • +7 more
Jul 8, 2022

AML Trial in Wuhan (CAR--?dT cells)

Recruiting
  • AML
  • CAR--γδT cells
  • Wuhan, Hubei, China
    Tongji Hospital
May 24, 2022

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy Trial in China (APG-2575, reduced-dose HHT, standard-dose HHT)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukaemia
  • Myeloid Malignancy
  • Beijing, Beijing, China
  • +9 more
Jan 10, 2022

Relapsed/Refractory AML Trial in Tianjin, Hangzhou (Uproleselan, Placebo)

Recruiting
  • Relapsed/Refractory AML
  • Tianjin, Tianjin, China
  • +1 more
Nov 22, 2021

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti-siglec-6 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti-siglec-6 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 2, 2022